Holen Sie sich die Stockscreener-App
14.48
1.46%
0.2067
Schlusskurs vom Vortag:
$14.27
Offen:
$14.28
24-Stunden-Volumen:
134.46K
Relative Volume:
0.10
Marktkapitalisierung:
$1.23B
Einnahmen:
$42.95M
Nettoeinkommen (Verlust:
$-130.01M
KGV:
-8.8934
EPS:
-1.6278
Netto-Cashflow:
$-19.66M
1W Leistung:
+1.82%
1M Leistung:
-8.83%
6M Leistung:
-18.02%
1J Leistung:
+199.76%
1-Tages-Spanne:
$14.28
$14.87
1-Wochen-Bereich:
$13.44
$14.87
52-Wochen-Spanne:
$4.79
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
14.45 | 1.22B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
Monte Rosa Therapeutics Announces Milestone Achievement - GlobeNewswire
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new hires get stock awards from Monte Rosa - Stock Titan
GLUE stock gains on investor conference plans and Monte Rosa outlook - AD HOC NEWS
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet? - simplywall.st
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC - MarketBeat
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Discipline and Rules-Based Execution in GLUE Response - Stock Traders Daily
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Guggenheim Reaffirms "Buy" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - MarketBeat
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - marketscreener.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Monte (GLUE) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Current Update; Session Move - vinanet.vn
Monte (GLUE) Shares: Finishes 6.28% Lower at $14.78 in Latest Trading; Key Range: the $14.04 to $15.52 Range Remains in Focus for the Current SessionSentiment Divergence - vinanet.vn
Monte (GLUE) Market Snapshot: Moves 1.30% Lower to $15.18 for the Current Session - vinanet.vn
Alphabet Inc. Buys Shares of 372,474 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - The Globe and Mail
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - marketbeat.com
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Monte Rosa Therapeutics (GLUE) Climbs 1.08% as Shares Hold Above Key Support at $15.09Time Weighted Price - vinanet.vn
JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - MarketBeat
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00 - marketbeat.com
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):